胃肠道间质瘤CD117、CD34和Ki-67的表达及其与临床病理因素和危险度的相关性
|
摘要
目的:探讨胃肠道间质瘤(gastrointestinal stromal tumor,GIST)CD117、CD34和Ki-67的表达率和表达强度及其与临床病理相关因素和危险度的关系。
方法:应用免疫组化S-P法检测57例GISTs的CD117、CD34和Ki-67的表达情况,并分析上述免疫组化指标在表达率方面与临床病理相关因素(性别、年龄、发生部位)的关系。并对这些病例进行危险度分级,进一步探讨上述免疫组化指标在表达程度方面与危险度之间的关系。
结果:CD117和CD34的阳性表达率分别为84.2%和71.9%;CD117和Ki-67阳性表达率在不同性别、年龄组、肠道和肠外之间均没有显著性差异(P＞0.05)。CD34阳性表达率在不同性别、年龄组之间没有显著性差异,但在肠道外GISTs阳性表达率高于肠道(P＜0.05)。CD34的阳性表达强度在不同的危险度之间没有显著性差异,CD117的阳性表达强度和Ki-67增殖指数在不同的危险度之间存在显著性差异(P＜0.05)。且CD117阳性表达强度、Ki-67增殖指数和危险度的分级呈正相关。
结论:CD117和CD34在GIST中呈高表达率,对GIST的诊断具有一定的意义。但CD34表达强度不能作为判断GIST危险度的指标;而CD117表达强度和Ki-67增殖指数和危险度的分级呈正相关,可能是判断GIST危险度的可靠指标之一。
Objective:To investigate the expression rates and the expression levels of CD117、CD34 and Ki-67 in gastrointestinal stromal tumors(GISTs) and its relationship with the clinicopathological features and risk rank of G1STs.
Methods:To detect the expression rates and the expression levels of CD117、CD34 and Ki-67 in 57 cases of GISTs by immunohistochemical S-P,and to analysis the relations of immunohistochemistry of the above indicators and related clinicopathological factors(gender, age,location).To further explore the relationship of the rank of risk and immunohistochemistry of the above indicators.
Results:The positive expression rates of CD117 and CD34 were 84.2%and 71.9%.;There had no significant difference in the different gender,age group,intestinal and parenteral on the positive expression rates of CD 117 and CD34(P＞0.05).There had no significant difference in the different gender and age group on the positive expression rates of CD34.The positive expression rates of CD34 in parenteral is higher than that of intestinal.The positive expression intensity of CD34 had no significant difference in different rank of risk.The positive Expression intensity of CD 117 and the proliferation index of Ki-67 is significant different in the different rank of risk(P＜0.05).The positive expression intensity of CD 117 and the proliferation index of Ki-67 was positively correlated with risk classification.
Conclusion:CD117 and CD34 in GIST was in high expression levels,and had a certain significance in the diagnosis of GIST.However,the expression intensity of CD34 can not be used as a risk indicator of GIST.And the expression intensity of CD117 and the proliferation index of Ki-67 was positively correlated with risk classification.They may be one of the reliable indicators in judging the risk of GIST.
方法:应用免疫组化S-P法检测57例GISTs的CD117、CD34和Ki-67的表达情况,并分析上述免疫组化指标在表达率方面与临床病理相关因素(性别、年龄、发生部位)的关系。并对这些病例进行危险度分级,进一步探讨上述免疫组化指标在表达程度方面与危险度之间的关系。
结果:CD117和CD34的阳性表达率分别为84.2%和71.9%;CD117和Ki-67阳性表达率在不同性别、年龄组、肠道和肠外之间均没有显著性差异(P＞0.05)。CD34阳性表达率在不同性别、年龄组之间没有显著性差异,但在肠道外GISTs阳性表达率高于肠道(P＜0.05)。CD34的阳性表达强度在不同的危险度之间没有显著性差异,CD117的阳性表达强度和Ki-67增殖指数在不同的危险度之间存在显著性差异(P＜0.05)。且CD117阳性表达强度、Ki-67增殖指数和危险度的分级呈正相关。
结论:CD117和CD34在GIST中呈高表达率,对GIST的诊断具有一定的意义。但CD34表达强度不能作为判断GIST危险度的指标;而CD117表达强度和Ki-67增殖指数和危险度的分级呈正相关,可能是判断GIST危险度的可靠指标之一。
Objective:To investigate the expression rates and the expression levels of CD117、CD34 and Ki-67 in gastrointestinal stromal tumors(GISTs) and its relationship with the clinicopathological features and risk rank of G1STs.
Methods:To detect the expression rates and the expression levels of CD117、CD34 and Ki-67 in 57 cases of GISTs by immunohistochemical S-P,and to analysis the relations of immunohistochemistry of the above indicators and related clinicopathological factors(gender, age,location).To further explore the relationship of the rank of risk and immunohistochemistry of the above indicators.
Results:The positive expression rates of CD117 and CD34 were 84.2%and 71.9%.;There had no significant difference in the different gender,age group,intestinal and parenteral on the positive expression rates of CD 117 and CD34(P＞0.05).There had no significant difference in the different gender and age group on the positive expression rates of CD34.The positive expression rates of CD34 in parenteral is higher than that of intestinal.The positive expression intensity of CD34 had no significant difference in different rank of risk.The positive Expression intensity of CD 117 and the proliferation index of Ki-67 is significant different in the different rank of risk(P＜0.05).The positive expression intensity of CD 117 and the proliferation index of Ki-67 was positively correlated with risk classification.
Conclusion:CD117 and CD34 in GIST was in high expression levels,and had a certain significance in the diagnosis of GIST.However,the expression intensity of CD34 can not be used as a risk indicator of GIST.And the expression intensity of CD117 and the proliferation index of Ki-67 was positively correlated with risk classification.They may be one of the reliable indicators in judging the risk of GIST.
引文
[1]Kindblom LG,Remotti HE,Aldenborg F,etal.Gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal[J].Am J Pathol,1998,152(5):1259-1269.
[2]Hirota S,Isozaki K,Moriiyama Y,etal.Gain-of-functionmutation of c-kit in human gastrointestinal stromal tumor[J].Science,1998,279(5350):577-580.
[3]刘晓红,马大烈,吴丽莉,等.原癌基因C-kit在胃肠道间质瘤中的表达及其临床意义[J].中华外科杂志,2002,40(4):277-279.
[4]冯菲,马大烈,刘伟强,等.巢蛋白(Nestin)在胃肠道间质瘤组织中的表达及其临床意义[J].实用癌症杂志,2004,12(1):24-26.
[5]Emory TS,Sobin LH,Lukes DH,et al.Prognosis of gastrointestinal smooth-musele(stromal)tumors,Dependence on anatomic sites[J].Am J Surg Pathol,1999,23(9):82-87.
[6]Can B,Sokmensuer C.clinicopathologic features,cellular differentiation,PCNA and P53expressions in gastrointestinal stromal tumors[J].Hepatogastroenterology,200350(Suppl2):ccⅹlⅲ-ccⅹlⅵ
[7]Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastro-intestinal stromal tumors:a consensusapproach[J].HumPathol,2002,33(5):159-165.
[8]Logrono R,Jones DV,Faruqi S,etal.Recent advances in cellbiology,diagnosis and therapy of gastrointestinal stroma]tumor(GIST)[J].Cancer BiolTher,2004,3(3):251-258.
[9]Lasota J,Jasinski M,Sarlomo-Rikala M,etal.Mutations inexonll of c-kit occur preferentialy in malignant versus benign gastro-intestinal stromal tumors and do not occur inleiomyomas or leio-myosarcomas[J].Am J Pathol,1999,154(1):53-60.
[10]Wasag B,Debiec-Rychter M,Pauwels P,etal.Diferential expression of KIT / PDGFRA mutant isoforms in epithelioid andmixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site[J].Mod Pathol,2004,17(8):889-894
[11]Fujimoto Y,Nakanishi Y,Yoshimura K,etal.Clinieopatho—logic study of primary malignant gastrointestinal stromal tumorof the stomach,with special reference to prognostic factors:analysis of results in 140 surgically resected patients[J].Gastric Cancer,2003,6(1):39-48.
[12]孔庆兖,卢敏华,陈菊荣,等.109例胃肠间质瘤临床病理研究[J].徐州医学院学报,2000,20(5):354-357.
[13]Wang L,Vargas H,French SW.Cefluar origin of gastrointestinal stromal tumors:a study of 27 cases[J].Arch Pathol LabMed,2000,124(10):1471-1475.
[14]Seidal T,Edvardsson H.Expression of c-kit(CD117)and Ki67 provides information ab out the possible cell of origin and clinical course of gastrointestinal stromal tumors [J].Histopathology,1999,34(5):416-424.
[15]Wang X,Mori I,Tang WH,etal.Gastrointestinal stromaltumors:clinieopathological study of Chinese cases[J].PatholInt,2001,51(9):701-706.
[16]卢强,何春燕,刘华安,等.胃肠道间质瘤临床病理分析及治疗.宁夏医学杂志2005,27(9):598-600.
[17]高文庆,李建胜,陈家林,等,31例胃肠道间质瘤的临床诊治分析.肿瘤研究与临床,2004,16(4):256-257.
[18]邱建龙,黄种心,吴春林,等,胃肠道和胃肠道外间质瘤临床病理分析.实用肿瘤学杂志,2005,19(78):276-278.
[19]帅晓明,韩高雄,陈俊华,等,胃肠道间质瘤28例临床和病理分析.腹部外科,2005,18(3):173-174.
[20]侯以岸,宋明,王宇,等,胃肠道间质瘤.中华实用医学,2000,2(10):27-29.
[21]廖松林,高冬霞,胃肠道间质瘤的进展.实用医院临床杂志,2004,1(3):13-14.
[22]徐熙善,朱寿田,洪中武,胃肠道间质瘤的临床表现及诊断[J].实用肿瘤学杂志,2005,19(77):205-206.
[23]高冬霞,孟凡农,田旭阳,等,胃肠道间质瘤的临床病理研究.中华普通外科杂志,2003,18(6):345-347.
[24]冯关荣,胃肠道间质瘤的诊治现状.医学文选,2006,25(2):322-323.
[25]宋明,王宇,胃肠道间质瘤研究进展.中华胃肠外科杂志2002,5(1):75-77.
[26]李乐平,靖昌庆,石玉龙,等,胃间质瘤的诊断及手术治疗.山东医药,200646(9):26-27.
[27]仲坚,徐立,李威,等,胃间质瘤的诊治探讨.江苏医药杂志,2005,3(11):65-66.
[28]钟全锦,陆爱权,胃间质瘤临床病理研究进展.广西医学,2002,24(11):1797-1799.
[29]王卓才,赖日权,黄小让,胃间质瘤相关基因蛋白及细胞增殖与预后的关系.诊断病理学杂志,2002,9(2):93-95.
[30]谭学君,杨践,朱延波,等,57例胃肠道间质瘤的临床病理及预后分析.广西医科大学学报,2003,20(1):83-85.
[31]柳萍,那加,张健波,等.CD117阳性小肠间质瘤中Ki67和P53蛋白的表达及在预后中 的意义[J].北京大学学报(医学版),2003,35(1):28-32
[32]Mittinen M,El-rifal W,Sobin LH,etal.Evaluation of Maligancy and prognosis of Gastrointestinal Stromal tumors[R],2002,33(5):478-183
[33]柳萍,那如,王颖,等.胃肠道间质瘤的光镜、免疫组织化学和超微结构的观察[J].中华病理学杂志,2002,31(3):199-203
[34]侯英勇,王坚,朱雄增,等.胃肠道间质瘤76例的临床病理及免疫组织化学特征[J].中华病理学杂志,2002,31(3):199-203.
[35]成文华,杨光华.77例胃肠道间质肿瘤的病理形态学及免疫组化研究[J].临床与实验病理学杂志,2001,17(7):123-127.
[36]江阳,梁延杰.恶性胃肠道间质瘤免疫组化与电镜研究[J].诊断病理杂志,2001,8:17-19
[37]Lasota J,Kopczynski J,Sarlomo-Rikala M,etal.KIT 1530ins6mutation defines a subset of predominantly malignant gastro-intestinal stromal tumors of intestinal origin[J].Hum Pathol,2003,34(12):1306-12
[38]孙兆田,刘亚东,鲍东梅.胃肠间质瘤-3例临床病理分析及免疫组化研究:[J].临床消化病杂志,2003,15(5):212.
[39]郭立新,杨光华.胃肠道间质肿瘤研究进展[J].中国肿瘤临床,2003,30(8):603-605.
[1]Van oosterom AT,Judson J,Verweij E,et al.Safety and efficacy of imatinib(STI571) in metastatic gastrointestinal stromal tumours:a phase Ⅰ study[J].The Lancet.2001,358,1421-23
[2]纪小龙,虞积耀。胃肠道平滑肌瘤[J]。诊断病理学杂志,2000,7(1):3-5
[3]Mazur MT,Clark HB.Gatric stromal tumors:reappraisal of histogenesis[J].Am J Surg Pathol.1983,7(16):507-519
[4]候英勇,朱雄增。胃肠道平滑肌瘤的组织发生及命名[J]。 中华病理学杂志,2000,29:453-457
[6]唐军。胃肠运动起搏器—Cajal间质细胞研究进展[J].。国外医学生理、病理科学预临床分册,2003,23(1):81-83
[7]M.Miettinen,J Y Blay,L H Sobin.Mesenchymal tumours of the stomach.WHO classification of tumours.Pathology and genetics of tumours of digestive system[M].Lyon:IARC Press,2000
[8]Miettinen M,Sarlomo-Rikala M,Lassota J.Gastrointestinal stromal tumors:recent advances in understanding of their biology[J].Hum Pathol.1999;30:1213-20
[9]Miettinen M,Lasota J.Gastrointestinal stromal tumors definition,clinical,histological,immumohistochemical,and molecular genetic features and differential diagnosis[J].Vichows Arch.2001;438:1-2
[10]候英勇,王坚,朱雄增等。胃肠道间质瘤76例的临床病例及免疫组织化学特征[J]。中华病理学杂志,2002,31(1):20-25
[11]冯菲。胃肠道间质瘤与酪氨酸激酶抑制剂。国外医学生理、病理科学与临床分册[J],2003,23(2):142-145
[12]Lewin KJ,Riddell RH,Weinstein WM,et al.Gastrointestinal pathology and its clinical implications[M].New York:Igaku-Shoin,1992.284-341
[13]Vannucchi M G.Receptors in intestinal cells of cajal:identi-fication and possible physiological roles[J].Microsd Resea Tech,1999,47:325-335
[14]Tsujimura K,Hashimoto K,Kitayma H,et al.Activating mutation in the catalytic domain of c-kit elicits hematopoietic trans-formation by receptor self-association not at the ligandinduceddimerizationsite[J].Blood,1999,93(4):1319-1329
[15]Lasota J,Jasinski M,Sarlomo-Rikala M,et al.Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas[J].Am J Pathol,1999,154(1):53-60
[16]Johanna A,Helena S,Jeanne MM,et al.The complexity of KIT gene mutations and chromosome rearrangements and their clini-cal correlation in gastrointestinal stromal(pacemaker cell) tumours[J].Am J Pathol,2002,160(1):15-22
[17]Hirota S,Isozaki K,Moriyama Y,et al.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J].Science,1998,279(5350):577-80
[18]回允中,主译.阿克曼外科病理学.上卷.第8版.沈阳:辽宁教育出版社,1999.645-647
[19]帅晓明,韩高雄,陈俊华,等,胃肠道间质瘤28例临床和病理分析.腹部外科,2005,18(3):173-174
[20]侯以岸,宋明,王宇,等,胃肠道间质瘤.中华实用医学,2000,2(10):27-29
[21]徐熙善,朱寿田,洪中武,胃肠道间质瘤的临床表现及诊断[J].实用肿瘤学杂志,2005,19(77):205-206.
[22]高冬霞,孟凡农,田旭阳,等,胃肠道间质瘤的临床病理研究.中华普通外科杂志,2003,18(6):345-347.
[23]王卓才,赖日权,黄小让,胃间质瘤相关基因蛋白及细胞增殖与预后的关系.诊断病理学杂志,2002,9(2):93-95.
[24]谭学君,杨践,朱延波,等,57例胃肠道间质瘤的临床病理及预后分析.广西医科大学学报,2003,20(1):83-85.
[25]De metri GD,von Mehren M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med,2002,347:472-480
[26]Erlandson RA,Klimstra DS,Woodruff JM.Subclassitieation of gastr intestinal stromal tumors based on evolution by dictmnmicroscopy and immunohistochemistry[J].Y1.trtmqt Pathol,1996,20:373-393.
[27]马大烈,郑青渝,李全华,等.微波EnVision免疫组织化学技术及其应用[J].中华病理学杂志.1998.27(2):153-154.
[28]Sarlomo.Rikala M.Kovatich A.Barusevicius A.et al.CDI17:a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34[J].Mod Pathol,1998,11:728-734
[29]罗容珍,梁小曼,何洁华,等,154例胃肠道间质瘤的临床病理及免疫组化特征.广东医学,2004.25(3):244-246.
[30]王莉,古丽娜.阿不拉江,谢辉,等,S-100蛋白在胃肠道间质瘤中的表达与生物学行为的 关系-附3例病例分析.中国医学研究与临床,2005,3(5):39-42.
[31]李敬果,徐秭,王聪,46例胃肠道间质瘤临床病理分析.河南肿瘤学杂志,2004,17(3):176-178.
[32]ChristopherD.M,Fletcher,Jules J,Berman,Christopher Codess,etal.Diagnosis of Gastrointestinal Stromal Tumor8:A Coll SensusApproach[J].HumanPathology,2002,33(5):459-465
[2]Hirota S,Isozaki K,Moriiyama Y,etal.Gain-of-functionmutation of c-kit in human gastrointestinal stromal tumor[J].Science,1998,279(5350):577-580.
[3]刘晓红,马大烈,吴丽莉,等.原癌基因C-kit在胃肠道间质瘤中的表达及其临床意义[J].中华外科杂志,2002,40(4):277-279.
[4]冯菲,马大烈,刘伟强,等.巢蛋白(Nestin)在胃肠道间质瘤组织中的表达及其临床意义[J].实用癌症杂志,2004,12(1):24-26.
[5]Emory TS,Sobin LH,Lukes DH,et al.Prognosis of gastrointestinal smooth-musele(stromal)tumors,Dependence on anatomic sites[J].Am J Surg Pathol,1999,23(9):82-87.
[6]Can B,Sokmensuer C.clinicopathologic features,cellular differentiation,PCNA and P53expressions in gastrointestinal stromal tumors[J].Hepatogastroenterology,200350(Suppl2):ccⅹlⅲ-ccⅹlⅵ
[7]Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastro-intestinal stromal tumors:a consensusapproach[J].HumPathol,2002,33(5):159-165.
[8]Logrono R,Jones DV,Faruqi S,etal.Recent advances in cellbiology,diagnosis and therapy of gastrointestinal stroma]tumor(GIST)[J].Cancer BiolTher,2004,3(3):251-258.
[9]Lasota J,Jasinski M,Sarlomo-Rikala M,etal.Mutations inexonll of c-kit occur preferentialy in malignant versus benign gastro-intestinal stromal tumors and do not occur inleiomyomas or leio-myosarcomas[J].Am J Pathol,1999,154(1):53-60.
[10]Wasag B,Debiec-Rychter M,Pauwels P,etal.Diferential expression of KIT / PDGFRA mutant isoforms in epithelioid andmixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site[J].Mod Pathol,2004,17(8):889-894
[11]Fujimoto Y,Nakanishi Y,Yoshimura K,etal.Clinieopatho—logic study of primary malignant gastrointestinal stromal tumorof the stomach,with special reference to prognostic factors:analysis of results in 140 surgically resected patients[J].Gastric Cancer,2003,6(1):39-48.
[12]孔庆兖,卢敏华,陈菊荣,等.109例胃肠间质瘤临床病理研究[J].徐州医学院学报,2000,20(5):354-357.
[13]Wang L,Vargas H,French SW.Cefluar origin of gastrointestinal stromal tumors:a study of 27 cases[J].Arch Pathol LabMed,2000,124(10):1471-1475.
[14]Seidal T,Edvardsson H.Expression of c-kit(CD117)and Ki67 provides information ab out the possible cell of origin and clinical course of gastrointestinal stromal tumors [J].Histopathology,1999,34(5):416-424.
[15]Wang X,Mori I,Tang WH,etal.Gastrointestinal stromaltumors:clinieopathological study of Chinese cases[J].PatholInt,2001,51(9):701-706.
[16]卢强,何春燕,刘华安,等.胃肠道间质瘤临床病理分析及治疗.宁夏医学杂志2005,27(9):598-600.
[17]高文庆,李建胜,陈家林,等,31例胃肠道间质瘤的临床诊治分析.肿瘤研究与临床,2004,16(4):256-257.
[18]邱建龙,黄种心,吴春林,等,胃肠道和胃肠道外间质瘤临床病理分析.实用肿瘤学杂志,2005,19(78):276-278.
[19]帅晓明,韩高雄,陈俊华,等,胃肠道间质瘤28例临床和病理分析.腹部外科,2005,18(3):173-174.
[20]侯以岸,宋明,王宇,等,胃肠道间质瘤.中华实用医学,2000,2(10):27-29.
[21]廖松林,高冬霞,胃肠道间质瘤的进展.实用医院临床杂志,2004,1(3):13-14.
[22]徐熙善,朱寿田,洪中武,胃肠道间质瘤的临床表现及诊断[J].实用肿瘤学杂志,2005,19(77):205-206.
[23]高冬霞,孟凡农,田旭阳,等,胃肠道间质瘤的临床病理研究.中华普通外科杂志,2003,18(6):345-347.
[24]冯关荣,胃肠道间质瘤的诊治现状.医学文选,2006,25(2):322-323.
[25]宋明,王宇,胃肠道间质瘤研究进展.中华胃肠外科杂志2002,5(1):75-77.
[26]李乐平,靖昌庆,石玉龙,等,胃间质瘤的诊断及手术治疗.山东医药,200646(9):26-27.
[27]仲坚,徐立,李威,等,胃间质瘤的诊治探讨.江苏医药杂志,2005,3(11):65-66.
[28]钟全锦,陆爱权,胃间质瘤临床病理研究进展.广西医学,2002,24(11):1797-1799.
[29]王卓才,赖日权,黄小让,胃间质瘤相关基因蛋白及细胞增殖与预后的关系.诊断病理学杂志,2002,9(2):93-95.
[30]谭学君,杨践,朱延波,等,57例胃肠道间质瘤的临床病理及预后分析.广西医科大学学报,2003,20(1):83-85.
[31]柳萍,那加,张健波,等.CD117阳性小肠间质瘤中Ki67和P53蛋白的表达及在预后中 的意义[J].北京大学学报(医学版),2003,35(1):28-32
[32]Mittinen M,El-rifal W,Sobin LH,etal.Evaluation of Maligancy and prognosis of Gastrointestinal Stromal tumors[R],2002,33(5):478-183
[33]柳萍,那如,王颖,等.胃肠道间质瘤的光镜、免疫组织化学和超微结构的观察[J].中华病理学杂志,2002,31(3):199-203
[34]侯英勇,王坚,朱雄增,等.胃肠道间质瘤76例的临床病理及免疫组织化学特征[J].中华病理学杂志,2002,31(3):199-203.
[35]成文华,杨光华.77例胃肠道间质肿瘤的病理形态学及免疫组化研究[J].临床与实验病理学杂志,2001,17(7):123-127.
[36]江阳,梁延杰.恶性胃肠道间质瘤免疫组化与电镜研究[J].诊断病理杂志,2001,8:17-19
[37]Lasota J,Kopczynski J,Sarlomo-Rikala M,etal.KIT 1530ins6mutation defines a subset of predominantly malignant gastro-intestinal stromal tumors of intestinal origin[J].Hum Pathol,2003,34(12):1306-12
[38]孙兆田,刘亚东,鲍东梅.胃肠间质瘤-3例临床病理分析及免疫组化研究:[J].临床消化病杂志,2003,15(5):212.
[39]郭立新,杨光华.胃肠道间质肿瘤研究进展[J].中国肿瘤临床,2003,30(8):603-605.
[1]Van oosterom AT,Judson J,Verweij E,et al.Safety and efficacy of imatinib(STI571) in metastatic gastrointestinal stromal tumours:a phase Ⅰ study[J].The Lancet.2001,358,1421-23
[2]纪小龙,虞积耀。胃肠道平滑肌瘤[J]。诊断病理学杂志,2000,7(1):3-5
[3]Mazur MT,Clark HB.Gatric stromal tumors:reappraisal of histogenesis[J].Am J Surg Pathol.1983,7(16):507-519
[4]候英勇,朱雄增。胃肠道平滑肌瘤的组织发生及命名[J]。 中华病理学杂志,2000,29:453-457
[6]唐军。胃肠运动起搏器—Cajal间质细胞研究进展[J].。国外医学生理、病理科学预临床分册,2003,23(1):81-83
[7]M.Miettinen,J Y Blay,L H Sobin.Mesenchymal tumours of the stomach.WHO classification of tumours.Pathology and genetics of tumours of digestive system[M].Lyon:IARC Press,2000
[8]Miettinen M,Sarlomo-Rikala M,Lassota J.Gastrointestinal stromal tumors:recent advances in understanding of their biology[J].Hum Pathol.1999;30:1213-20
[9]Miettinen M,Lasota J.Gastrointestinal stromal tumors definition,clinical,histological,immumohistochemical,and molecular genetic features and differential diagnosis[J].Vichows Arch.2001;438:1-2
[10]候英勇,王坚,朱雄增等。胃肠道间质瘤76例的临床病例及免疫组织化学特征[J]。中华病理学杂志,2002,31(1):20-25
[11]冯菲。胃肠道间质瘤与酪氨酸激酶抑制剂。国外医学生理、病理科学与临床分册[J],2003,23(2):142-145
[12]Lewin KJ,Riddell RH,Weinstein WM,et al.Gastrointestinal pathology and its clinical implications[M].New York:Igaku-Shoin,1992.284-341
[13]Vannucchi M G.Receptors in intestinal cells of cajal:identi-fication and possible physiological roles[J].Microsd Resea Tech,1999,47:325-335
[14]Tsujimura K,Hashimoto K,Kitayma H,et al.Activating mutation in the catalytic domain of c-kit elicits hematopoietic trans-formation by receptor self-association not at the ligandinduceddimerizationsite[J].Blood,1999,93(4):1319-1329
[15]Lasota J,Jasinski M,Sarlomo-Rikala M,et al.Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas[J].Am J Pathol,1999,154(1):53-60
[16]Johanna A,Helena S,Jeanne MM,et al.The complexity of KIT gene mutations and chromosome rearrangements and their clini-cal correlation in gastrointestinal stromal(pacemaker cell) tumours[J].Am J Pathol,2002,160(1):15-22
[17]Hirota S,Isozaki K,Moriyama Y,et al.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J].Science,1998,279(5350):577-80
[18]回允中,主译.阿克曼外科病理学.上卷.第8版.沈阳:辽宁教育出版社,1999.645-647
[19]帅晓明,韩高雄,陈俊华,等,胃肠道间质瘤28例临床和病理分析.腹部外科,2005,18(3):173-174
[20]侯以岸,宋明,王宇,等,胃肠道间质瘤.中华实用医学,2000,2(10):27-29
[21]徐熙善,朱寿田,洪中武,胃肠道间质瘤的临床表现及诊断[J].实用肿瘤学杂志,2005,19(77):205-206.
[22]高冬霞,孟凡农,田旭阳,等,胃肠道间质瘤的临床病理研究.中华普通外科杂志,2003,18(6):345-347.
[23]王卓才,赖日权,黄小让,胃间质瘤相关基因蛋白及细胞增殖与预后的关系.诊断病理学杂志,2002,9(2):93-95.
[24]谭学君,杨践,朱延波,等,57例胃肠道间质瘤的临床病理及预后分析.广西医科大学学报,2003,20(1):83-85.
[25]De metri GD,von Mehren M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med,2002,347:472-480
[26]Erlandson RA,Klimstra DS,Woodruff JM.Subclassitieation of gastr intestinal stromal tumors based on evolution by dictmnmicroscopy and immunohistochemistry[J].Y1.trtmqt Pathol,1996,20:373-393.
[27]马大烈,郑青渝,李全华,等.微波EnVision免疫组织化学技术及其应用[J].中华病理学杂志.1998.27(2):153-154.
[28]Sarlomo.Rikala M.Kovatich A.Barusevicius A.et al.CDI17:a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34[J].Mod Pathol,1998,11:728-734
[29]罗容珍,梁小曼,何洁华,等,154例胃肠道间质瘤的临床病理及免疫组化特征.广东医学,2004.25(3):244-246.
[30]王莉,古丽娜.阿不拉江,谢辉,等,S-100蛋白在胃肠道间质瘤中的表达与生物学行为的 关系-附3例病例分析.中国医学研究与临床,2005,3(5):39-42.
[31]李敬果,徐秭,王聪,46例胃肠道间质瘤临床病理分析.河南肿瘤学杂志,2004,17(3):176-178.
[32]ChristopherD.M,Fletcher,Jules J,Berman,Christopher Codess,etal.Diagnosis of Gastrointestinal Stromal Tumor8:A Coll SensusApproach[J].HumanPathology,2002,33(5):459-465